Perfluorocarbons Therapeutics in Modern Cancer Nanotechnology for Hypoxiainduced Anti-tumor Therapy.
Satija, S
Sharma, P
Kaur, H
Dhanjal, DS
Chopra, RS
Khurana, N
Vyas, M
Sharma, N
Tambuwala, MM
Bakshi, HA
Charbe, NB
Zacconi, FC
Chellappan, DK
Dua, K
Mehta, M
- Publisher:
- Bentham Science Publishers Ltd.
- Publication Type:
- Journal Article
- Citation:
- Curr Pharm Des, 2021, 27, (43), pp. 4376-4387
- Issue Date:
- 2021
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
19118806_8004973280005671.pdf | Published version | 2.91 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Satija, S | |
dc.contributor.author | Sharma, P | |
dc.contributor.author | Kaur, H | |
dc.contributor.author | Dhanjal, DS | |
dc.contributor.author | Chopra, RS | |
dc.contributor.author | Khurana, N | |
dc.contributor.author | Vyas, M | |
dc.contributor.author | Sharma, N | |
dc.contributor.author | Tambuwala, MM | |
dc.contributor.author | Bakshi, HA | |
dc.contributor.author | Charbe, NB | |
dc.contributor.author | Zacconi, FC | |
dc.contributor.author | Chellappan, DK | |
dc.contributor.author |
Dua, K https://orcid.org/0000-0002-7507-1159 |
|
dc.contributor.author | Mehta, M | |
dc.date.accessioned | 2022-05-30T22:42:51Z | |
dc.date.available | 2021-06-28 | |
dc.date.available | 2022-05-30T22:42:51Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Curr Pharm Des, 2021, 27, (43), pp. 4376-4387 | |
dc.identifier.issn | 1381-6128 | |
dc.identifier.issn | 1873-4286 | |
dc.identifier.uri | http://hdl.handle.net/10453/157831 | |
dc.description.abstract | With an estimated failure rate of about 90%, immunotherapies that are intended for the treatment of solid tumors have caused an anomalous rise in the mortality rate over the past decades. It is apparent that resistance towards such therapies primarily occurs due to elevated levels of HIF-1 (Hypoxia-induced factor) in tumor cells, which are caused by disrupted microcirculation and diffusion mechanisms. With the advent of nanotechnology, several innovative advances were brought to the fore; and, one such promising direction is the use of perfluorocarbon nanoparticles in the management of solid tumors. Perfluorocarbon nanoparticles enhance the response of hypoxia-based agents (HBAs) within the tumor cells and have been found to augment the entry of HBAs into the tumor micro-environment. The heightened penetration of HBAs causes chronic hypoxia, thus aiding in the process of cell quiescence. In addition, this technology has also been applied in photodynamic therapy, where oxygen self-enriched photosensitizers loaded perfluorocarbon nanoparticles are employed. The resulting processes initiate a cascade, depleting tumour oxygen and turning it into a reactive oxygen species eventually to destroy the tumour cell. This review elaborates on the multiple applications of nanotechnology based perfluorocarbon formulations that are being currently employed in the treatment of tumour hypoxia. | |
dc.format | ||
dc.language | eng | |
dc.publisher | Bentham Science Publishers Ltd. | |
dc.relation.ispartof | Curr Pharm Des | |
dc.relation.isbasedon | 10.2174/1381612827666210830100907 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1115 Pharmacology and Pharmaceutical Sciences | |
dc.subject.classification | Medicinal & Biomolecular Chemistry | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Fluorocarbons | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Nanoparticles | |
dc.subject.mesh | Nanotechnology | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Photochemotherapy | |
dc.subject.mesh | Photosensitizing Agents | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Fluorocarbons | |
dc.subject.mesh | Photosensitizing Agents | |
dc.subject.mesh | Photochemotherapy | |
dc.subject.mesh | Nanotechnology | |
dc.subject.mesh | Nanoparticles | |
dc.subject.mesh | Tumor Microenvironment | |
dc.title | Perfluorocarbons Therapeutics in Modern Cancer Nanotechnology for Hypoxiainduced Anti-tumor Therapy. | |
dc.type | Journal Article | |
utslib.citation.volume | 27 | |
utslib.location.activity | United Arab Emirates | |
utslib.for | 1115 Pharmacology and Pharmaceutical Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2022-05-30T22:42:50Z | |
pubs.issue | 43 | |
pubs.publication-status | Published | |
pubs.volume | 27 | |
utslib.citation.issue | 43 |
Abstract:
With an estimated failure rate of about 90%, immunotherapies that are intended for the treatment of solid tumors have caused an anomalous rise in the mortality rate over the past decades. It is apparent that resistance towards such therapies primarily occurs due to elevated levels of HIF-1 (Hypoxia-induced factor) in tumor cells, which are caused by disrupted microcirculation and diffusion mechanisms. With the advent of nanotechnology, several innovative advances were brought to the fore; and, one such promising direction is the use of perfluorocarbon nanoparticles in the management of solid tumors. Perfluorocarbon nanoparticles enhance the response of hypoxia-based agents (HBAs) within the tumor cells and have been found to augment the entry of HBAs into the tumor micro-environment. The heightened penetration of HBAs causes chronic hypoxia, thus aiding in the process of cell quiescence. In addition, this technology has also been applied in photodynamic therapy, where oxygen self-enriched photosensitizers loaded perfluorocarbon nanoparticles are employed. The resulting processes initiate a cascade, depleting tumour oxygen and turning it into a reactive oxygen species eventually to destroy the tumour cell. This review elaborates on the multiple applications of nanotechnology based perfluorocarbon formulations that are being currently employed in the treatment of tumour hypoxia.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph